Keyphrases
Patients with Cancer
100%
Tumor Angiogenesis
100%
VE-cadherin
100%
Circulating Endothelial Cells
100%
Cancer Patients
66%
Pregnant Women
50%
Hematological Malignancies
33%
MRNA Level
33%
Angiogenic
33%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
33%
CD133
33%
Clinical Trials
16%
Endothelial Cells
16%
Quantitative Evaluation
16%
Quantitative PCR
16%
Newly Diagnosed
16%
Healthy Controls
16%
Response Predictors
16%
Treatment Outcome
16%
Progenitor Cells
16%
Complete Remission
16%
Malignant Disease
16%
Cell Markers
16%
Factor Level
16%
Antiangiogenic Therapy
16%
Antiangiogenic Agents
16%
Angiogenesis Markers
16%
Circulating RNA
16%
Plasma Vascular Endothelial Growth Factor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Malignant Neoplasm
100%
Vascular Endothelial Cadherin
100%
Hematologic Malignancy
33%
Vasculotropin Receptor 2
33%
Clinical Trial
16%
Remission
16%
Vasculotropin
16%
Angiogenesis Inhibitor
16%
Antiangiogenic Therapy
16%
Diseases
16%
Biochemistry, Genetics and Molecular Biology
Angiogenesis
100%
RNA
100%
VE-cadherin
100%
Kinase Insert Domain Receptor
28%
CD133
28%
Clinical Trial
14%
Quantitative Technique
14%
Progenitor Cell
14%
Vascular Endothelial Growth Factor
14%
Quantitative Reverse Transcription Polymerase Chain Reaction
14%
Normal Value
14%
Blood Plasma
14%
Immunology and Microbiology
Angiogenesis
100%
VE-cadherin
100%
Kinase Insert Domain Receptor
33%
Blood Plasma
16%
Quantitative Reverse Transcription Polymerase Chain Reaction
16%
Vasculotropin
16%
Angiogenesis Inhibitor
16%
Normal Value
16%